First patient treated in the EffiKIR trial
Update on clinical trials with IPH2101 in Multiple Myeloma
First clinical trial with IPH2102/BMS-986015 sponsored by Bristol-Myers Squibb announced
Results of IPH2101 Phase I trial in AML published in BLOOD
Innate Pharma receives regulatory authorization to start randomized Phase II trial with IPH2102 in Acute Myeloid Leukemia
Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement for an Investigational Immuno-Oncology Biologic
Innate Pharma receives a milestone payment for IPH2201, a monoclonal antibody licensed to Novo Nordisk A/S
The US National Cancer Institute starts a Phase II clinical trial with Innate Pharma's IPH2101
Initiation of a Phase II clinical trial with anti-KIR monoclonal antibody IPH2101 in smoldering myeloma patients
Final data on response rate for the Phase II trial with IPH 1101 in Follicular Lymphoma reported at the EHA meeting
